Initiator Pharma
7.25
SEK
-2.03 %
INIT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-2.03%
+0.69%
-7.64%
-27.5%
-21.54%
-21.88%
-10.49%
+6.72%
+61.62%
www.initiatorpharma.com/en
Initiator Pharma is a biotechnology company. Today, the main focus is to develop drug candidates to be used in treatment of erectile dysfunction in men. The company currently has pharmaceuticals in clinical stage testing for patients that do not respond on PDE5i pharmaceuticals. Initiator Pharma was created as a spin-off from Saniona and is today based in Åbyhøj.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
INIT
Daily low / high price
7.25 / 7.4
SEK
Market cap
407.15M SEK
Turnover
9.48K SEK
Volume
1.3K
Financial calendar
Annual report
28.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Linc AB | 18.0 % | 18.0 % |
| Adrigo Asset Management | 6.5 % | 6.5 % |
| Avanza Pension | 5.9 % | 5.9 % |
| Mac Clinical Research Finance LTD | 5.5 % | 5.5 % |
| Claus Elsborg Olesen | 2.4 % | 2.4 % |
| Dan Peters | 2.2 % | 2.2 % |
| Nordnet Pensionsförsäkring | 1.7 % | 1.7 % |
| Annika Espander Jansson | 1.7 % | 1.7 % |
| Mikael Thomsen | 1.5 % | 1.5 % |
| Mats Thorén | 1.4 % | 1.4 % |
ShowingAll content types
INITIATOR PHARMA: Q3 2024 REPORT
Completion of capital increase in Initiator Pharma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools